• Multiple Myeloma Program

    Dana-Farber/Brigham and Women's Cancer Care

    The Multiple Myeloma program is part of the Hematologic Oncology (Blood Cancers) Treatment Center. Our specialists are highly experienced in treating patients with multiple myeloma.

    About the Program

    The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics provides comprehensive care to patients with multiple myeloma, including promising new therapies through clinical trials rooted in an approach that brings laboratory discoveries quickly to the clinical setting. We conduct an active program of basic and clinical research aimed at improving the outcomes of multiple myeloma.

    The Bing Center for Waldenström's macroglobulinemia provides comprehensive, state-of-the-art care, including promising new therapies through clinical trials, to patients with Waldenström's macroglobulinemia and related IgM disorders.

    Our Treatment Approach

    We provide a comprehensive range of services for patients, including:

     

    The Treatment Team

    The program encompasses physicians, clinicians and a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies. Physicians work closely with research scientists in a "bench-to-bedside" approach that identifies promising new treatments by rapidly translating laboratory discoveries into the clinical setting.

    Multiple Myeloma Program Leadership

    Kenneth C. Anderson, MD, Program Director
    Paul G. Richardson, MD, Clinical Director

    Multiple Myeloma Physicians

    Kenneth C. Anderson, MD
    Jorge J. Castillo, MD
    Irene Ghobrial, MD
    Jacob Laubach, MD
    Nikhil C. Munshi, MD
    Claudia Paba-Prada, MD
    Paul G. Richardson, MD
    Robert L. Schlossman, MD
    Steven P. Treon, MD, PhD 

    Multiple Myeloma Research Scientists

    Dharminder Chauhan, PhD
    Ruben Carrasco, MD, PhD
    Teru Hideshima, MD, PhD
    Jana Jakubikova, PhD
    Stefan Klippel, PhD
    Douglas McMillin, PhD
    Constantine Mitsiades, MD, PhD
    Melissa Ooi, MD
    Klaus Podar, MD, PhD
    Weihua Song, MD
    Yu-tzu Tai, PhD

    Multiple Myeloma Nursing Team

    Stacey Chuma, RN, BSN
    Kathleen Colson, RN
    Kristen Cummings, RN
    Virginia Dalton, NP
    Heidi DiPietro, RN
    Deborah Doss, RN, BSN
    Kathleen Finn, RN
    Tina Flaherty, NP
    Muriel Gannon, RN
    Mary McKenney, NP
    Kim Noonan, NP

     

    Clinical Research

    The Lipper Center and LeBow Institute for Myeloma Therapeutics encompass a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for multiple myeloma and, someday, a cure. At any given time, dozens of studies and clinical trials for multiple myeloma are underway.

    Our program is a founding institution of the Multiple Myeloma Research Consortium (MMRC), which brings together distinguished researchers and world-renowned academic institutions to speed translation of research to clinical care for myeloma patients.

    The center's research in the laboratory and the clinic is focused on several areas. These include investigations of the genetic abnormalities of myeloma cells; studies of the complex signaling that enables myeloma cells to grow and resist both conventional chemotherapy and novel therapy; efforts to unleash the power of the immune system against myeloma; and explorations of the way in which myeloma cells interact with their environment in the bone marrow and outside the marrow compartment. The mission of this research is to identify and validate novel targets in myeloma, so that new therapies aimed at these targets can be developed, leading to improved outcomes and a cure.

    The center offers patients access to a wide range of clinical research trials. These include studies aimed at improving the outcomes of patients undergoing high-dose chemotherapy and stem cell transplantation, as well as trials using agents like thalidomide and its immunomodulatory derivatives, proteasome inhibitors, which attempt to kill myeloma cells directly and also make it impossible for them to grow in the marrow "neighborhood." The center also has clinical research trials evaluating supportive therapies, such as bisphosphonates.

     

    Contact Us

    New Patients

    Multiple Myeloma: 617-632-3823 or 617-632-5138, or use this online form to make an appointment.

    Current Patients

    Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.

    Fax

    617-632-3730 

    Mailing address

    Hematologic Malignancies Division
    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

     
     
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • New adult multiple myeloma patients:
      617-632-3823 or 617-632-5138 
    • Or complete the online form.
     
  • New Therapies, Progress for Multiple Myeloma

    • Paul Richardson, Nikhil Munshi, and Ken AndersonThe 21st century has seen great strides in treatment for multiple myeloma, a cancer of the bone marrow. Read how research by Dana-Farber scientists has helped to make this blood cancer a manageable illness for many patients.